Sotera Health (NASDAQ:SHC) Releases Earnings Results, Misses Expectations By $0.01 EPS

Sotera Health (NASDAQ:SHC) posted its quarterly earnings results on Tuesday. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01), Briefing.com reports. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The company had revenue of $285.47 million for the quarter, compared to analyst estimates of $278.64 million. During the same quarter in the prior year, the business posted $0.18 earnings per share. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. Sotera Health updated its FY 2024 guidance to 0.670-0.750 EPS and its FY24 guidance to $0.67-0.75 EPS.

Sotera Health Stock Performance

Shares of NASDAQ:SHC traded down $0.50 on Thursday, hitting $15.61. The company had a trading volume of 164,160 shares, compared to its average volume of 1,301,697. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44. The stock has a market cap of $4.42 billion, a price-to-earnings ratio of 64.44 and a beta of 2.08. The stock has a 50 day moving average price of $15.96 and a 200 day moving average price of $13.69. The company has a current ratio of 2.93, a quick ratio of 2.59 and a debt-to-equity ratio of 5.46.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SHC. Citigroup upped their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Barclays increased their target price on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a research note on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Insider Transactions at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the transaction, the director now directly owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 55.12% of the stock is owned by corporate insiders.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.